Stephen Willey
Stock Analyst at Stifel
(3.98)
# 540
Out of 5,157 analysts
132
Total ratings
45.36%
Success rate
13.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stephen Willey
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZYME Zymeworks | Maintains: Buy | $40 → $47 | $25.46 | +84.60% | 8 | Mar 3, 2026 | |
| ACLX Arcellx | Downgrades: Hold | $127 → $115 | $114.39 | +0.53% | 2 | Feb 24, 2026 | |
| IRON Disc Medicine | Maintains: Buy | $125 → $110 | $66.18 | +66.21% | 2 | Feb 17, 2026 | |
| INCY Incyte | Maintains: Buy | $119 → $120 | $96.02 | +24.97% | 8 | Feb 11, 2026 | |
| EXEL Exelixis | Maintains: Hold | $43 → $44 | $41.29 | +6.56% | 20 | Feb 11, 2026 | |
| NRIX Nurix Therapeutics | Maintains: Buy | $33 → $35 | $15.90 | +120.13% | 6 | Jan 29, 2026 | |
| CELC Celcuity | Maintains: Buy | $68 → $115 | $117.10 | -1.79% | 2 | Nov 13, 2025 | |
| NKTX Nkarta | Maintains: Buy | $12 → $11 | $2.57 | +328.02% | 5 | Nov 11, 2025 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | $30 → $9 | $4.66 | +93.13% | 3 | Aug 29, 2025 | |
| INSM Insmed | Maintains: Buy | $121 → $145 | $143.85 | +0.80% | 8 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $3.57 | +96.08% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $12.54 | +123.29% | 1 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6 → $5 | $3.43 | +45.77% | 4 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $25 → $20 | $4.26 | +369.48% | 4 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $100 | $16.00 | +525.00% | 5 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $1.63 | +145.40% | 3 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $20.06 | +134.30% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $0.31 | +1,190.32% | 7 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $4 | $2.24 | +78.57% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $53 → $62 | $60.61 | +2.29% | 5 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $5.57 | +61.58% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.99 | +503.02% | 1 | Nov 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $228 → $288 | $1.73 | +16,547.40% | 4 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $21 | $2.45 | +757.14% | 2 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 → $4 | $1.66 | +140.96% | 7 | Jul 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $123 | $322.38 | -61.85% | 3 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $48 → $47 | $75.66 | -37.88% | 2 | Aug 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $102 → $109 | $60.89 | +79.01% | 3 | Aug 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Terminates: Hold | n/a | $22.41 | - | 2 | Jun 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $23 | $7.07 | +225.32% | 5 | Feb 7, 2018 |
Zymeworks
Mar 3, 2026
Maintains: Buy
Price Target: $40 → $47
Current: $25.46
Upside: +84.60%
Arcellx
Feb 24, 2026
Downgrades: Hold
Price Target: $127 → $115
Current: $114.39
Upside: +0.53%
Disc Medicine
Feb 17, 2026
Maintains: Buy
Price Target: $125 → $110
Current: $66.18
Upside: +66.21%
Incyte
Feb 11, 2026
Maintains: Buy
Price Target: $119 → $120
Current: $96.02
Upside: +24.97%
Exelixis
Feb 11, 2026
Maintains: Hold
Price Target: $43 → $44
Current: $41.29
Upside: +6.56%
Nurix Therapeutics
Jan 29, 2026
Maintains: Buy
Price Target: $33 → $35
Current: $15.90
Upside: +120.13%
Celcuity
Nov 13, 2025
Maintains: Buy
Price Target: $68 → $115
Current: $117.10
Upside: -1.79%
Nkarta
Nov 11, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $2.57
Upside: +328.02%
X4 Pharmaceuticals
Aug 29, 2025
Maintains: Buy
Price Target: $30 → $9
Current: $4.66
Upside: +93.13%
Insmed
Aug 14, 2025
Maintains: Buy
Price Target: $121 → $145
Current: $143.85
Upside: +0.80%
Aug 8, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $3.57
Upside: +96.08%
Jun 25, 2025
Initiates: Buy
Price Target: $28
Current: $12.54
Upside: +123.29%
May 14, 2025
Maintains: Hold
Price Target: $6 → $5
Current: $3.43
Upside: +45.77%
May 13, 2025
Maintains: Hold
Price Target: $25 → $20
Current: $4.26
Upside: +369.48%
Mar 21, 2025
Maintains: Buy
Price Target: $240 → $100
Current: $16.00
Upside: +525.00%
Feb 27, 2025
Maintains: Buy
Price Target: $8 → $4
Current: $1.63
Upside: +145.40%
Oct 8, 2024
Initiates: Buy
Price Target: $47
Current: $20.06
Upside: +134.30%
Aug 20, 2024
Maintains: Buy
Price Target: $8 → $4
Current: $0.31
Upside: +1,190.32%
Dec 19, 2023
Maintains: Buy
Price Target: $3 → $4
Current: $2.24
Upside: +78.57%
Dec 18, 2023
Maintains: Buy
Price Target: $53 → $62
Current: $60.61
Upside: +2.29%
Jan 27, 2023
Initiates: Buy
Price Target: $9
Current: $5.57
Upside: +61.58%
Nov 28, 2022
Initiates: Buy
Price Target: $12
Current: $1.99
Upside: +503.02%
Jun 26, 2020
Downgrades: Hold
Price Target: $228 → $288
Current: $1.73
Upside: +16,547.40%
Mar 17, 2020
Maintains: Buy
Price Target: $22 → $21
Current: $2.45
Upside: +757.14%
Jul 29, 2019
Downgrades: Hold
Price Target: $10 → $4
Current: $1.66
Upside: +140.96%
Aug 13, 2018
Maintains: Buy
Price Target: $125 → $123
Current: $322.38
Upside: -61.85%
Aug 8, 2018
Maintains: Hold
Price Target: $48 → $47
Current: $75.66
Upside: -37.88%
Aug 3, 2018
Maintains: Buy
Price Target: $102 → $109
Current: $60.89
Upside: +79.01%
Jun 25, 2018
Terminates: Hold
Price Target: n/a
Current: $22.41
Upside: -
Feb 7, 2018
Maintains: Buy
Price Target: $20 → $23
Current: $7.07
Upside: +225.32%